Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) EBT: 2017-2025

Historic EBT for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$78.6 million.

  • Autolus Therapeutics' EBT rose 4.25% to -$78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.2 million, marking a year-over-year increase of 18.51%. This contributed to the annual value of -$219.1 million for FY2024, which is 5.15% down from last year.
  • Latest data reveals that Autolus Therapeutics reported EBT of -$78.6 million as of Q3 2025, which was down 65.37% from -$47.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' EBT registered a high of -$7.4 million during Q4 2022, and its lowest value of -$39.4 billion during Q3 2021.
  • Over the past 3 years, Autolus Therapeutics' median EBT value was -$52.7 million (recorded in 2024), while the average stood at -$56.5 million.
  • As far as peak fluctuations go, Autolus Therapeutics' EBT plummeted by 87,053.61% in 2021, and later soared by 99.89% in 2022.
  • Autolus Therapeutics' EBT (Quarterly) stood at -$24.1 million in 2021, then soared by 69.23% to -$7.4 million in 2022, then plummeted by 939.10% to -$77.2 million in 2023, then surged by 66.13% to -$26.1 million in 2024, then grew by 4.25% to -$78.6 million in 2025.
  • Its EBT stands at -$78.6 million for Q3 2025, versus -$47.5 million for Q2 2025 and -$67.9 million for Q1 2025.